Tokyo, July 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058648) titled 'Real world use of biomarker testing using blood-based liquid biopsy in Japan' on July 30.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - MSD K.K
Condition:
Condition - malignant tumor
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To describe treatment and testing patterns, as well as clinical characteristics of patients who underwent biomarker testing using liquid biopsy in Japan.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who have at least 1 record for a liquid biopsy test (FoundationOne Liquid or Guardant360).
Key exclusion criteria - There are no exclusion criteria for this study.
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2023 Year 02 Month 22 Day
Date of IRB - 2023 Year 03 Month 15 Day
Anticipated trial start date - 2023 Year 07 Month 01 Day
Last follow-up date - 2023 Year 07 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061817
Disclaimer: Curated by HT Syndication.
